Thomas Ulmer
Director/Board Member at Aravax Pty Ltd.
Profile
Thomas Ulmer is a Non-Executive Director at Aravax Pty Ltd.
He was previously a Co-Managing Director at Immatics Biotechnologies GmbH from 2018 to 2020 and Head of Planning, Forecasting & Resource Allocation at Merck KGaA from 2012 to 2016.
He also served as Chief Financial Officer at Immatics NV.
Ulmer holds an MBA from the University of Giessen.
Thomas Ulmer active positions
Companies | Position | Start |
---|---|---|
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Director/Board Member | 2020-10-31 |
Former positions of Thomas Ulmer
Companies | Position | End |
---|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Executive Officer | 2020-02-11 |
MERCK KGAA | Corporate Officer/Principal | 2016-06-30 |
IMMATICS N.V. | Director of Finance/CFO | - |
Training of Thomas Ulmer
University of Giessen | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
IMMATICS N.V. | Health Technology |
MERCK KGAA | Health Technology |
Private companies | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Health Technology |
- Stock Market
- Insiders
- Thomas Ulmer